Effect of trapidil on serum lipid and apolipoprotein levels in patients with ischemic heart disease.
1. Serum total cholesterol (TCH), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein (LDL-C), atherosclerotic index (AI) and apolipoprotein (apo A-I, A-II, B, C-II, C-III and E) levels were investigated in patients with ischemic heart disease before and after medication of trapidil. 2. Twenty-one patients were orally given 100 mg of trapidil, three times daily (300 mg/day). After 8 weeks' administration, serum HDL-C level increased (P < 0.01) and AI decreased (P < 0.02) significantly, whereas TCH, TG and LDL-C levels tended to decrease but not significantly. 3. Among the parameters of apolipoproteins, apo A-I, a main protein of HDL-C, was significantly increased (P < 0.05) by trapidil. 4. These results indicate that trapidil has a beneficial effect on the coronary risk profile as reflected by lipid measurements.
Kotake
H
H
First Department of Internal Medicine, Tottori University School of Medicine, Yonago, Japan.
Sawada
Y
Y
Hoshio
A
A
Shirota
K
K
Nawada
T
T
Yoshida
A
A
Hisatome
I
I
Miyakoda
H
H
Mashiba
H
H
D000368:Aged; D001053:Apolipoproteins / Q000097:blood*; D008076:Cholesterol, HDL / Q000097:blood; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000097:blood*; D014192:Trapidil / Q000494:pharmacology*
D001053:Apolipoproteins; D008076:Cholesterol, HDL; D008055:Lipids; D014192:Trapidil